Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

Nephrology Dialysis Transplantation

Volumn 30, Issue 6, 2015, Pages 1037-1046

  Floege, Jürgen ^a   Covic, Adrian C ^b   Ketteler, Markus ^c   Mann, Johannes F E ^d   Rastogi, Anjay ^e   Spinowitz, Bruce ^f   Chong, Edward M F ^g   Gaillard, Sylvain ^g   Lisk, Laura J ^g   Sprague, Stuart M ^h  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c KfH Kidney Center Coburg   (Germany)

^d Munich General Hospital   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NEW YORK HOSPITAL QUEENS   (United States)

^g Vifor (International) Inc   (Switzerland)

^h NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

hemodialysis; peritoneal dialysis; sucroferric oxyhydroxide

Indexed keywords

ALKALINE PHOSPHATASE; FERRITIN; HEMOGLOBIN; IRON; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER CARBONATE; SUCROFERRIC OXYHYDROXIDE; TRANSFERRIN; DRUG COMBINATION; FERRIC ION; SUCROSE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; FERRITIN BLOOD LEVEL; HEADACHE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; IRON BLOOD LEVEL; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; ADVERSE EFFECTS; CLINICAL TRIAL; DRUG COMBINATION; METABOLISM; PROGNOSIS; RENAL REPLACEMENT THERAPY; TIME;

DRUG COMBINATIONS; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; IRON; MALE; MIDDLE AGED; PHOSPHORUS; PROGNOSIS; RENAL DIALYSIS; SUCROSE; TIME FACTORS;

EID: 84939610397     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv006     Document Type: Article

References (17)

1. Hruska KA, Mathew S. The roles of the skeleton and phosphorus in the CKD mineral bone disorder. Adv Chronic Kidney Dis 2011; 18: 98-104
2. Block GA. Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 2001; 10: 741-747
3. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
4. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305: 1119-1127
5. Kanbay M, Goldsmith D, Akcay A et al. Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif 2009; 27: 220-230
6. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
7. Isakova T, Gutierrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20: 388-396
8. Lopes AA, Tong L, Thumma J et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012; 60: 90-101
9. Cannata-Andia JB, Fernandez-Martin JL, Locatelli F et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013; 84: 998-1008
10. Arenas MD, Malek T, Gil MT et al. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol 2010; 23: 525-534
11. Chiu YW, Teitelbaum I, Misra M et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1089-1096
12. Toussaint ND, Pedagogos E, Beavis J et al. Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. Nephrol Dial Transpl 2011; 26: 1319-1326
13. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 2010; 74: 4-11
14. Wüthrich RP, Chonchol M, Covic A et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8: 280-289
15. Floege J, Covic AC, Ketteler M et al. Efficacy and safety of a novel iron-based phosphate binder in dialysis patients, in a Phase III study. Kidney Int 2014; 86: 638-647
16. th European Peritoneal Dialysis (EuroPD) Meeting, 11-14 October 2013, Maastricht, The Netherlands
17. Wang S, Alfieri T, Ramakrishnan K et al. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant 2014; 29: 2092-2099